TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Oct. 28, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company...
EHR
Travere Therapeutics Reports Third Quarter 2022 Financial Results
EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second...
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and...
INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 26, 2022...
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from...
Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases
Proteros selected by Adrestia for its cutting-edge structure-based drug discovery engineProteros to support Adrestia in the discovery of first-in-class drugs...
Press release Biocartis Group NV: Biocartis Reports Results of Third Quarter of 2022
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA...
MEDIROM Healthcare Technologies Inc. Announces September 2022 Key Performance Indicators (KPIs)
Total Customers Served: 71,770 – Sales Per Customer: JPY 6,505 – Customer Repeat Ratio: 80.8% September 2022_Number of Salons September...
Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting
Company will exhibit Gimoti® and meet with Key Opinion Leaders Healio Industry Breakthrough Product Award Nominee SOLANA BEACH, Calif., Oct....
Collegium to Report Third Quarter 2022 Financial Results on November 3, 2022
STOUGHTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced...
PolyPid Announces Cost Reduction Plan
Reduction of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3 2023 PolyPid Intends to Discuss...
Cocrystal Pharma to Present at the LD Micro Main Event XV
BOTHELL, Wash., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam...
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference
NEW YORK, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA), a biotechnology company developing breakthrough immunomodulation therapies...
H1 Unveils New Brand on the Heels of Significant Financial, Customer and Product Capabilities Growth
With a refined mission to connect the world with the right doctors, new acquisition and enhanced global data solutions, H1...
PETVIVO HOLDINGS, INC. TO PRESENT AT LD MICRO MAIN EVENT XV
PetVivo Holdings, Inc. John LaiMINNEAPOLIS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an...
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference...
CORRECTION — SOLVE FSHD invests US$10 Million in Vita Therapeutics
VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- In a release issued today by SOLVE FSHD under the same headline,...
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage...
Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022
First presentation of ERADICATE phase 3 study dataStudy met its primary and secondary endpoints comparing ceftobiprole versus daptomycin with or...
BioSyent Initiates First Dividend
MISSISSAUGA, Ontario, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce...